Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - September 2017

ADME PK

September is always a busy time for conferences. This month Cyprotex presented at the BMSS meeting in Manchester, the EUROTOX congress in Bratislava, the DMG meeting in London, the SPS meeting in Berlin and the North American ISSX meeting in Rhode Island. You can access the posters and presentations from these events below.

Earlier this month, Dr Mohammed Atari, Senior Mathematical Modeller at Cyprotex, attended the prestigious IPEM awards ceremony in  London to receive the Innovation Early Career award. This award was presented in recognition of Mohammed's contribution to scientific modelling through the development of novel models to predict pharmaceutical properties. 

We would also like to announce some exciting news from our parent company, Evotec. In August, Evotec completed the acquisition of Aptuit. The acquisition not only increases capabilities within integrated drug discovery projects, but greatly expands service offering within preclinical development, enhancing our IND-enabling and integrated CMC expertise. Learn more about the Aptuit acquisition and further updates from Evotec below.

New research - download our recent posters and presentation

Learn more about our research presented at recent conferences.

Investigation and application of APGC-MS and LC-MS methods for the analysis of EU-ToxRisk compounds in in vitro ADME samples.

Download poster

A high content screening approach to genotoxicity testing: detection of DNA damage and differentiation of clastogens and aneugens utilising histone biomarkers.

Download poster

Development and evaluation of 3D in vitro models for the prediction of tissue specific toxicities.

Download slides

Cardiotoxicity evaluation of chronic BMS-986094 exposure in human iPSC-derived cardiomyocytes using a microelectrode array (MEA) assay.

Download poster

Evaluating the pharmacology and neurotoxic predictability of neuroactive compounds using human induced pluripotent stem cell-derived glutamatergic neurons co-cultured with astrocytes using a microelectrode array platform.

Download poster

Application of a low intrinsic clearance assay in preclinical drug discovery.

Download poster

Multiparametric in vitro toxicity approaches to understand the hepatotoxic mechanism of action of Fasiglifam (TAK-875).

Download poster

Download posters
 
Cyprotex Senior Mathematical Modeller receives prestigious IPEM award

Mohammed Atari PhD, Senior Mathematical Modeller at Cyprotex receives the IPEM Innovation Early Career award for his contribution to scientific modelling.

Learn more

Learn more
 
Highlights from our parent company, Evotec

Evotec acquires Aptuit, expanding leadership in external innovation.

Learn more

Read our COO Mario Polywka’s interview in Nature “Cutting to the chase for efficient drug discovery.”

Learn more

European Investment Bank supports Evotec’s Innovate Strategy with a €75M loan for first-in-class drug discovery projects.

Learn more

Evotec & MaRS innovation establish ‘Lab150’ academic bridge in Toronto.

Learn more

Evotec & Abivax enter into strategic collaboration to develop novel antiviral agents.

Learn more

Evotec invests in Exscientia to advance AI-driven drug discovery.

Learn more


Learn more



Learn more


Learn more
 
Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close